RxDoctor Payments Data

Joseph Chebli

Surgery · Venice, FLNPI 1649215435

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,165 of the $1,761 with a category attached, or 66.2%. Boston Scientific accounts for 73.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $1,341 and has fallen 94.5% since, to $74 in 2025. That places this record below the midpoint for surgery clinicians in FL, where the typical reported total is $2,683.

$1,761in general payments, 2019–2025

Across 24 payments — averaging $73.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Johnson & Johnson$202
  • Intra-sana Laboratories$131
  • Novo Nordisk$64
  • Lilly USA, LLC$22
  • Phathom Pharmaceuticals, Inc.$16
  • plus $28 from 2 others

What the payments were for

  • Travel & lodging$1,16566%
  • Food & beverage$59634%

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific10$1,299
Johnson & Johnson6$202
Intra-sana Laboratories1$131
Novo Nordisk3$64
Lilly USA, LLC1$22
Phathom Pharmaceuticals, Inc.1$16
Coastal Medical Technologies LLC1$14
Intuitive Surgical1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,761 in reported general payments places this provider in the 40th percentile of 1,569 surgery providers in Florida.

See all surgery providers in Florida →

Medicare billing

Part B allowed, 2024
$29,535
Medicare patients
104
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$68,440
Omeprazole90$1,048
Ondansetron OdtOndansetron49$289
Folic Acid11$238
Pantoprazole Sodium13$215
Tramadol Hcl11$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$64$68,44041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,569 surgery providers in Florida.

Other surgery in Venice

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →